Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

87
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
87
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

601
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
601
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

751
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
751
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

182
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
182

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human Papillomavirus in Men: An Updated Review of its Clinical and Epidemiological Relevance.

Actas dermo-sifiliograficas·2026
Same author

Consensus Document on the Clinical Management of Alopecia Areata: Recommendations from the Spanish Hair Research Group of the Spanish Academy of Dermatology and Venerology.

Actas dermo-sifiliograficas·2026
Same author

[Translated article] Hyperhidrosis, Anticholinergics, and Dementia.

Actas dermo-sifiliograficas·2025
Same author

[Translated article] Update of the Spanish Consensus Document on Infantile Hemangioma.

Actas dermo-sifiliograficas·2025
Same author

Update of the Spanish Consensus Document on Infantile Hemangioma.

Actas dermo-sifiliograficas·2025
Same author

[Translated article] What Proportion of the Spanish Dermatology Caseload Corresponds to Pediatric Dermatoses? Results From the DIADERM National Random Sampling Survey.

Actas dermo-sifiliograficas·2023
Same journal

Fingolimod-associated lymphomatoid papulosis.

Actas dermo-sifiliograficas·2026
Same journal

Demodicosis: update and treatment with laser and other light sources.

Actas dermo-sifiliograficas·2026
Same journal

New treatments for adult female acne.

Actas dermo-sifiliograficas·2026
Same journal

First regulations of the Spanish Society of Dermatology (1909).

Actas dermo-sifiliograficas·2026
Same journal

Long-hair FUE: advantages and disadvantages of the most recent technique in hair transplantation.

Actas dermo-sifiliograficas·2026
Same journal

Sunburns, Tanning, and Social Media: A Descriptive Study Among Spanish University Students.

Actas dermo-sifiliograficas·2026
See all related articles

Related Experiment Video

Updated: May 24, 2025

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.8K

Hyperhidrosis, Anticholinergics, and Dementia.

J Del Boz1, J C Bautista Vidal2

  • 1Servicio de Dermatología, Hospital Regional Universitario de Málaga, Málaga, España.

Actas Dermo-Sifiliograficas
|March 2, 2025
PubMed
Summary
This summary is machine-generated.

Oral anticholinergics effectively treat hyperhidrosis but may be linked to dementia. This review examines the controversial connection between anticholinergic use for excessive sweating and dementia risk.

Keywords:
AnticholinergicsAnticolinérgicosDemenciaDementiaHiperhidrosisHyperhidrosisOxibutininaOxybutynin

More Related Videos

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

13.9K
Transcranial Direct Current Stimulation tDCS for Memory Enhancement
10:37

Transcranial Direct Current Stimulation tDCS for Memory Enhancement

Published on: September 18, 2021

13.6K

Related Experiment Videos

Last Updated: May 24, 2025

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.8K
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

13.9K
Transcranial Direct Current Stimulation tDCS for Memory Enhancement
10:37

Transcranial Direct Current Stimulation tDCS for Memory Enhancement

Published on: September 18, 2021

13.6K

Area of Science:

  • Neurology
  • Dermatology
  • Pharmacology

Background:

  • Oral anticholinergics are frequently used off-label for hyperhidrosis treatment, with demonstrated efficacy and a generally favorable safety profile.
  • Recent research suggests a potential association between anticholinergic use and dementia development, especially in older adults.
  • Emerging evidence also proposes hyperhidrosis as a potential early indicator of dementia.

Purpose of the Study:

  • To review and synthesize current data on the controversial topic of oral anticholinergic use for hyperhidrosis and its potential link to dementia.
  • To investigate whether treating hyperhidrosis with anticholinergics is associated with an increased risk of developing dementia.

Main Methods:

  • Literature review of existing studies, including clinical trials, on anticholinergic use for hyperhidrosis.
  • Analysis of research associating anticholinergic medications with dementia risk.
  • Examination of studies suggesting hyperhidrosis as an early dementia symptom.

Main Results:

  • Anticholinergics are effective for hyperhidrosis, with studies showing good safety.
  • Separate research links anticholinergic use to dementia, particularly in the elderly.
  • No studies to date have directly investigated the link between anticholinergics prescribed for hyperhidrosis and dementia development.

Conclusions:

  • The potential link between oral anticholinergics used for hyperhidrosis and dementia remains an under-researched but important area.
  • Further investigation is warranted to clarify the safety profile of long-term anticholinergic use for hyperhidrosis concerning cognitive health.